Dr. Federico V. Pallardó Calatayud

Principal Investigator
Research Group on Cellular and Organic Physiopathology of Oxidative Stress

Presentation

Dr. Pallardó studied Medicine at the Faculty of Medicine of the University of Valencia where he graduated in 1985 with the qualification of outstanding where he also obtained his doctorate “cum laude”.
After passing through the universities of Oxford in the United Kingdom and Harvard Medical School in the United States, where he obtained the prestigious NATO fellowship, he returned to Spain in 1992. He is currently a University Professor, being Dean of the Faculty of Medicine and Dentistry from the University of Valencia between 2011 and 2017. He has been a visiting professor at the Chicago Medical School.
He has been director of the Central Research Unit, coordinating the INCLIVA basic research laboratories for more than ten years. He has been the head of the CIBER group in its rare diseases division since 2007.
His research focuses on the role of oxidative stress in the pathophysiology of rare diseases and epigenetic regulation. He has more than 230 scientific publications, is a regular contributor to prestigious international journals and has directed 23 doctoral theses. Its h-index is currently 57 with more than 11,000 accumulated citations. He is a founding partner of the biotechnological company EPIDISEASE S.L. spin-off of the University of Valencia, CIBERER and INCLIVA. It holds four international patents. He directs the CIBERER-Biobank of the ISCIII.

He has been secretary of the SFRR (Europe) and has received various national and international awards such as the Fundación Salud 2000 Award for his research into rare diseases or the international project Saving lives at Birth from the Bill and Melinda Gates Foundation. He has been awarded the “SFRR-Europe Annual Award Lecture” by the Society for Free Radical Research in its 2020 edition.
He has been an advisory member of the Valencian Foundation for Advanced Studies and Jury of the Jaime I research awards on several occasions. He is an evaluator of research projects for national organizations from different countries in Europe and Latin America. He belongs to the editorial committee of several journals and is editor of “Redox Biology”

Dr. Federico V. Pallardó Calatayud
Principal
Investigator
Dr. Federico V. Pallardó Calatayud

federico.v.pallardo@uv.es  

Publications
Alterations in leukocyte DNA methylome are associated to immunosuppression in severe clinical phenotypes of septic patients. Beltran-Garcia J, Casabo-Valles G, Osca-Verdegal R, Navarrete-Lopez P, Rodriguez-Gimillo M, Nacher-Sendra E, Ferrando-Sanchez C, Garcia-Lopez E, Pallardo F, Carbonell N, Mena-Molla S, Garcia-Gimenez J. Frontiers in Immunology. 2024 Jan 3:14:1333705. doi: 10.3389/fimmu.2023.1333705. PMID: 38235139

Oxidative stress and metabolism meet epigenetic modulation in physical exercise. Garcia-Gimenez J, Canovas-Cervera I, Pallardo F. Free Radical Biology & Medicine. 2024 Jan 8:213:123-137. doi: 10.1016/j.freeradbiomed.2024.01.008. PMID: 38199289

Age-Related microRNA overexpression in Lafora disease male mice provides links between neuroinflammation and oxidative stress. Roma-Mateo C, Lorente-Pozo S, Marquez-Thibaut L, Moreno-Estelles M, Garces C, Gonzalez D, Lahuerta M, Aguado C, Garcia-Gimenez JL, Sanz P, Pallardo FV. International Journal of Molecular Sciences. 2023 Jan 6;24(2):1089. doi: 10.3390/ijms24021089. PMID: 36674605

Exacerbated response to oxidative stress in the Retinitis Pigmentosa CerklKD/KO mouse model triggers retinal degeneration pathways upon acute light stress. García-Arroyo R, Domènech E, Herrera-Ubeda C, Asensi M, de Arenas C, Cuezva J, Garcia-Fernàndez J, Pallardó F, Mirra S, Marfany G. Redox Biology. 2023 Oct:66:102862. doi: 10.1016/j.redox.2023.102862. PMID: 37660443

Extracellular histones trigger oxidative stress-dependent induction of the NF-kB/CAM pathway via TLR4 in endothelial cells. Perez-Cremades D, Bueno-Beti C, Garcia-Gimenez J, Ibanez-Cabellos J, Pallardo F, Hermenegildo C, Novella S. Journal of Physiology and Biochemistry. 2023 May;79(2):251-260. doi: 10.1007/s13105-022-00935-z. PMID: 36464762

Oxidative stress and epigenetics: miRNA involvement in rare autoimmune diseases. Ibanez-Cabellos J, Pallardo F, Garcia-Gimenez J, Seco-Cervera M. Antioxidants. 2023 Mar 25;12(4):800. doi: 10.3390/antiox12040800. PMID: 37107175

Persistent pulmonary fibrotic sequelae in patients with telomere shortening one year after severe COVID-19. Mulet A, González-Cabo P, Pallardó FV, Signes-Costa J. Archivos de Bronconeumologia. 2023 Nov 10:S0300-2896(23)00365-4. doi: 10.1016/j.arbres.2023.11.003. PMID: 37985282

The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Mayayo-Vallverdu C, de Heredia M, Prat E, Gonzalez L, Guarch M, Vilches C, Munoz L, Asensi M, Serra C, Llebaria A, Casado M, Artuch R, Garrabou G, Garcia-Roves P, Pallardo F, Nunes V. Redox Biology. 2023 Aug;64:102801. doi: 10.1016/j.redox.2023.102801. PMID: 37418888

Validation of circulating histone detection by mass spectrometry for early diagnosis, prognosis, and management of critically ill septic patients. Garcia-Gimenez J, Garcia-Lopez E, Mena-Molla S, Beltran-Garcia J, Osca-Verdegal R, Nacher-Sendra E, Aguado-Velasco C, Casabo-Valles G, Roma-Mateo C, Rodriguez-Gimillo M, Antunez O, Ferreres J, Pallardo F, Carbonell N. Journal of Translational Medicine. 2023 May 23;21(1):344. doi: 10.1186/s12967-023-04197-1. PMID: 37221624

Characterization of Early Peripheral Immune Responses in Patients with Sepsis and Septic Shock. Beltran-Garcia J, Osca-Verdegal R, Javega B, Herrera G, O’Connor J, Garcia-Lopez E, Casabo-Valles G, Rodriguez-Gimillo M, Ferreres J, Carbonell N, Pallardo F, Garcia-Gimenez J. Biomedicines. 2022 Feb 23;10(3):525. doi: 10.3390/biomedicines10030525. PMID: 35327327

CIBERER: Spanish national network for research on rare diseases: a highly productive collaborative initiative. Luque J, Mendes I, Gomez B, Morte B, de Heredia M, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Perez-Jurado L, Montoliu L, Carracedo A, Millan J, Webb S, Palau F, Lapunzina P, Pallardo Calatayud F, CIBERER Network. Clinical Genetics. 2022 May;101(5-6):481-493. doi: 10.1111/cge.14113. PMID: 35060122

Clinical and immunological aspects of microRNAs in neonatal sepsis. Fatmi A, Chabni N, Cernada M, Vento M, Gonzalez-Lopez M, Aribi M, Pallardo FV, Garcia-Gimenez JL. Biomedicine & Pharmacotherapy. 2021 Nov 19;145:112444. doi: 10.1016/j.biopha.2021.112444. PMID: 34808550

Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, Novella S, Hermenegildo C, Pallardó FV, García-Giménez JL. Journal of Inflammation Research. 2022 Jul 25;15:4217-4238. doi: 10.2147/JIR.S363693. PMID: 35915852

Frataxin deficit leads to reduced dynamics of growth cones in dorsal root ganglia neurons of Friedreich’s Ataxia YG8sR model: a multilinear algebra approach. Munoz Lasso D, Molla B, Saenz Gamboa J, Insuasty E, de la Iglesia Vaya M, Pook M, Pallardo F, Palau F, Gonzalez-Cabo P. Frontiers in Molecular Neuroscience. 2022 Jun 13;15:912780. doi: 10.3389/fnmol.2022.912780. PMID: 35769335

Histone citrullination mediates a protective role in endothelium and modulates inflammation. Osca-Verdegal R, Beltran-Garcia J, Paes A, Nacher-Sendra E, Novella S, Hermenegildo C, Carbonell N, Garcia-Gimenez J, Pallardo F. Cells. 2022 Dec 15;11(24):4070. doi: 10.3390/cells11244070. PMID: 36552833

Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies. Garcia-Gimenez JL, Garcia-Trevijano ER, Aviles-Alia AI, Ibanez-Cabellos JS, Bovea-Marco M, Bas T, Pallardo FV, Vina JR, Zaragoza R. Orphanet Journal of Rare Diseases. 2022 Dec 27;17(1):450. doi: 10.1186/s13023-022-02603-3. PMID: 36575500

Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity. Saadi W, Fatmi A, Pallardo FV, Garcia-Gimenez JL, Mena-Molla S. Cancers. 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184. PMID: 36612180

Neurodevelopmental outcome and epigenetic changes at 2 years associated with the oxygen load received upon postnatal stabilization: a pilot study. Lorente-Pozo S, Boronat N, Parra-Llorca A, Lara-Canton I, Solaz-Garcia A, Soler J, Buso E, Casabo-Valles G, Garcia-Gimenez J, Pallardo F, Vento M. Neonatology. 2022;119(5):575-584. doi: 10.1159/000525305. PMID: 35760056

The endothelial glycocalyx and neonatal sepsis. Fatmi A, Saadi W, Beltran-Garcia J, Garcia-Gimenez JL, Pallardo FV. International Journal of Molecular Sciences. 2022 Dec 26;24(1):364. doi: 10.3390/ijms24010364. PMID: 36613805

The genetic diversity and dysfunctionality of catalase associated with a worse outcome in Crohn’s Disease. Iborra M, Moret I, Buso E, Garcia-Gimenez J, Ricart E, Gisbert J, Cabre E, Esteve M, Marquez-Mosquera L, Garcia-Planella E, Guardiola J, Pallardo F, Serena C, Algaba-Chueca F, Domenech E, Nos P, Beltran B. International Journal of Molecular Sciences. 2022 Dec 14;23(24):15881. doi: 10.3390/ijms232415881. PMID: 36555526

Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases?. Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA. Antioxidants. 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165. PMID: 35052668

Use of circular RNAs in diagnosis, prognosis and therapeutics of renal cell carcinoma. Osca Verdegal R, Beltran Garcia J, Gorriz J, Jabaloyas J, Pallardo F, Garcia Gimenez J. Frontiers in Cell and Developmental Biology. 2022 Jun 22;10:879814. doi: 10.3389/fcell.2022.879814. PMID: 35813211

Cofilin and neurodegeneration: new functions for an old but gold protein. Lapena-Luzon T, Rodriguez L, Beltran-Beltran V, Beneto N, Pallardo F, Gonzalez-Cabo P. Brain Sciences. 2021 Jul 20;11(7):954. doi: 10.3390/brainsci11070954. PMID: 34356188

Comparative analysis of chromatin-delivered biomarkers in the monitoring of sepsis and septic shock: a pilot study. Beltran-Garcia J, Manclus J, Garcia-Lopez E, Carbonell N, Ferreres J, Rodriguez-Gimillo M, Garces C, Pallardo F, Garcia-Gimenez J, Montoya A, Roma-Mateo C. International Journal of Molecular Sciences. 2021 Sep 14;22(18):9935. doi: 10.3390/ijms22189935. PMID: 34576097

DNA Methylation Analysis to Unravel Altered Genetic Pathways Underlying Early Onset and Late Onset Neonatal Sepsis. A Pilot Study. Lorente-Pozo S, Navarrete P, Garzón MJ, Lara-Cantón I, Beltrán-García J, Osca-Verdegal R, Mena-Mollá S, García-López E, Vento M, Pallardó FV, García-Giménez JL. Frontiers in Immunology. 2021 Feb 15;12:622599. doi: 10.3389/fimmu.2021.622599. PMID: 33659006

Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. Pallardo Calatayud F, Pagano G, Rodriguez Melguizo L, González Cabo P, Lyakhovich A, Trifuoggi M. Translational Research. 2021 Mar;229:135-141. doi: 10.1016/j.trsl.2020.08.009. PMID: 32841735

IGF-1 haploinsufficiency causes age-related chronic cochlear inflammation and increases noise-induced hearing loss. Celaya A, Rodriguez-De la Rosa L, Bermudez-Munoz J, Zubeldia J, Roma-Mateo C, Avendano C, Pallardo F, Varela-Nieto I. Cells. 2021 Jul 3;10(7):1686. doi: 10.3390/cells10071686. PMID: 34359856

Implementing Precision Medicine in Human Frailty through Epigenetic Biomarkers. Garcia-Gimenez J, Mena-Molla S, Tarazona-Santabalbina F, Vina J, Gomez-Cabrera M, Pallardo F. International Journal of Environmental Research and Public Health. 2021 Feb 15;18(4):1883. doi: 10.3390/ijerph18041883. PMID: 33672064

Mitigating the pro-oxidant state and melanogenesis of Retinitis pigmentosa: by counteracting mitochondrial dysfunction. Pagano G, Pallardo F, Lyakhovich A, Tiano L, Trifuoggi M. Cellular and Molecular Life Sciences. 2021 Dec;78(23):7491-7503. doi: 10.1007/s00018-021-04007-1. PMID: 34718826

Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia. Pagano G, Manfredi C, Pallardo Calatayud F, Lyakhovich A, Tiano L, Trifuoggi M. Inflammation Research. 2021 Feb;70(2):159-170. doi: 10.1007/s00011-020-01423-0. PMID: 33346851

Role of adenosine receptors in rare neurodegenerative diseases with motor symptoms. Beltran-Beltran V, Beneto N, Lapena-Luzon T, Rodriguez LR, Pallardo FV, Gonzalez-Cabo P. Current Protein & Peptide Science. 2021 Dec 27;22(9):675-694. doi: 10.2174/1389203722666210910110126. PMID: 34514988

Role of microRNAs as biomarkers in sepsis-associated encephalopathy. Osca-Verdegal R, Beltran-Garcia J, Pallardo FV, Garcia-Gimenez JL. Molecular Neurobiology. 2021 Sep;58(9):4682-4693. doi: 10.1007/s12035-021-02445-3. PMID: 34160774

Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis. Beltran Garcia J, Osca Verdegal R, Nacher Sendra E, Cardona Monzonis A, Sanchis Gomar F, Carbonell N, Pallardo FV, Lavie CJ, Garcia Gimenez JL. Progress in Cardiovascular Diseases. 2021;68:70-77. doi: 10.1016/j.pcad.2021.07.005. PMID: 34265333

Projects
Reference: PI22/00507
Title: Reposicionamiento de fármacos como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos.
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico V. Pallardó Calatayud, Juan Antonio Navarro Langa
Duration: 2023 – 2025
Total budget: 147.620,00 €
Reference: IFEQ22/00178
Title: Sistema de espectrometría de masas acoplado a un sistema de cromatografía líquida de alta precisión
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2022 – 2022
Total budget: 300.000 €
Reference: DTS21/00193
Title: Test basados en péptidos spike-in y espectrometría de masas para la cuantificación de histonas circulantes y proteína APC, para el manejo clínico del paciente crítico
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Jose Luis García Giménez
Duration: 2022 – 2023
Total budget: 122.100 €
Reference: GVA-COVID19/2021/028
Title: Efecto de la infección por COVID-19 sobre la longitud del telómero y parámetros de función mitocondrial y su relación con la evolución a fibrosis pulmonar de tipo idiopático
Funding body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2021 – 2022
Total budget: 62.280 €
Reference: AP-2021-009
Title: NATAX: Nanozimas como aproximación terapéutica para el tratamiento del estrés oxidativo en la ataxia de Friedreich
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: José Vicente Ros Lis, Federico V. Pallardó Calatayud
Duration: 2021 – 2022
Total budget: 4.750 €
Reference: 90/C/2020
Title: Therapeutical strategies for cystinuria
Funding body: Marató TV3
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2021 – 2023
Total budget: 35.580 €
Reference: PI19/01084
Title: Nuevas terapias en ataxia de Friedreich
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2020 – 2022
Total budget: 93.170 €
Reference: DTS17/00132
Title: Kit multiplex para la detección simultánea de biomarcadores de diagnóstico y pronóstico de sepsis y shock séptico por espectrometría de masas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2018 – 2020
Total budget: 78.210 €
Reference: PROMETEO/2018/135
Title: From genes to therapy in neurodegenerative and neuromuscular disorders
Funding body: Conselleria de Educación, Investigación, Cultura y Deporte
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2018 – 2021
Total budget: 310.506 €
Reference: PI16/01031
Title: Respuestas epigenéticas a cambios en el entorno redox nuclear. Posibles dianas terapéuticas en enfermedades raras
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2017 – 2019
Total budget: 105.875 €
Reference: CB06/07/0073
Title: CIBER de Enfermedades Raras (CIBERer)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2007 –
Total budget:
+ Info
Title: Mecanismos moleculares implicados en las interacciones entre macromoléculas derivadas de la cromatina y células endoteliales: potencial para el desarrollo de biomarcadores de sepsis
Doctoral candidate: Garcés Díaz, Concepción
Director(s): Pallardó Calatayud, Federico; Romá Mateo, Carlos
Date of the defense: 19/12/2023
University: University de Valencia

Title: Identificación de los mecanismos epigenéticos relacionados con los fenómenos de inmunosupresión en sepsis y su uso como biomarcadores de pronóstico
Doctoral candidate: Osca Verdegal, Rebeca
Director(s):
Date of the defense: 19/05/2023
University: University de Valencia

Title: Papel de las membranas asociadas a retículo endoplasmático y mitocondria (MAMS) en la fisiopatología celular de la ataxia de Friedrich y su relevancia como diana terapéutica
Doctoral candidate: Robles Rodríguez, Laura
Director(s): Pallardo Calatayud, Federico; González Cabo, María Pilar
Date of the defense: 20/01/2023
University: Universitat de València

Title: Uso de las histonas circulantes y sus modificaciones post-traduccionales como biomarcadores en sepsis y shock séptico
Doctoral candidate: Beltrán García, Jesús
Director(s): García Giménez, José Luis; Pallardó Calatayud, Federico
Date of the defense: 20/01/2022
University: Universitat de València

Title: Proteínas nucleares y otros mediadores de inflamación en pacientes en shock séptico sometidos a terapias de remplazo renal
Doctoral candidate: Crespo Gomez, Mónica
Director(s): Cervera Montes, Manuel; Pallardó Calatayud, Federico; Romá Mateo, Carlos
Date of the defense: 25/06/2021
University: Universitat de València